Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro

详细信息    查看全文

• 作者：Pushpendra Singh ; Felix Bast
• 关键词：Cancer ; InterBioScreen library ; Natural compounds ; Maestro 9.6 ; In silico ; In vitro
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：32
• 期：9
• 全文大小：7,950 KB
• 参考文献：1.Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999;17(1):94–5.CrossRef PubMed
  2.Costantino L, Barlocco D. Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry. Future Med Chem. 2013;5(1):5–7.CrossRef PubMed
  3.Landis-Piwowar K, Chen D, Foldes R, Chan T-H, Dou QP. Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009-present). Expert Opin Ther Pat. 2013;23(2):189–202.CrossRef PubMed
  4.Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 2010;17(1):R39–52.PubMedCentral CrossRef PubMed
  5.Nagle DG, Ferreira D, Zhou Y-D. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67(17):1849–55.PubMedCentral CrossRef PubMed
  6.Hsu C-H, Tsai T-H, Kao Y-H, Hwang K-C, Tseng T-Y, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008;27(3):363–70.CrossRef PubMed
  7.Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014;31(1):1–14.CrossRef
  8.Li J, Zhou N, Luo K, Zhang W, Li X, Wu C, et al. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy. Int J Mol Sci. 2014;15(9):15994–6011.PubMedCentral CrossRef PubMed
  9.Yim-Im W, Sawatdichaikul O, Semsri S, Horata N, Mokmak W, Tongsima S, et al. Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinform. 2014;15(1):1–13.CrossRef
  10.X-q Sun, Chen L, Y-z Li, W-h Li, Liu G-x, Tu Y-q, et al. Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors. Acta Pharmacol Sin. 2014;35(2):301–10.CrossRef
  11.Liu L, Leung K, Chan DS, Wang Y, Ma D, Leung C. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis. 2014;5(6):e1293.CrossRef PubMed
  12.Mayer AM, Gustafson KR. Marine pharmacology in 2005–2006: antitumour and cytotoxic compounds. Eur J Cancer. 2008;44(16):2357–87.PubMedCentral CrossRef PubMed
  13.Mayer AM, Gustafson KR. Marine pharmacology in 2001–2: antitumour and cytotoxic compounds. Eur J Cancer. 2004;40(18):2676–704.CrossRef PubMed
  14.Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548–57.CrossRef PubMed
  15.da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol. 2001;1(4):364–9.CrossRef PubMed
  16.Sunil H. Inhibition studies of naturally occurring terpene based compounds with cyclin-dependent kinase 2 enzyme. J Comput Sci Syst Biol. 2012;5:2.
  17.Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66(7):3347–50.CrossRef PubMed
  18.Hillman GG. Dietary agents in cancer chemoprevention and treatment. J Oncol. 2012. doi:10.​1155/​2012/​749310 .
  19.Phosrithong N, Ungwitayatorn J. Molecular docking study on anticancer activity of plant-derived natural products. Med Chem Res. 2010;19(8):817–35.CrossRef
  20.Cho JY, Park J. Contribution of natural inhibitors to the understanding of the PI3 K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade. Int J Mol Sci. 2008;9(11):2217–30.PubMedCentral CrossRef PubMed
  21.Singh P, Bast F. Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components. Med Chem Res. 2014;23(4):1690–700.CrossRef
  22.Singh P, Bast F. Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro. Invest New Drugs. 2015;33(3):575–93.CrossRef PubMed
  23.Singh P, Bast F. In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. Med Chem Res. 2014;23(12):5074–85.CrossRef
  24.Singh P, Bast F. High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3. Med Chem Res. 2015;24(6):2694–708.CrossRef
  25.Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177–96.CrossRef PubMed
  26.Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–9.CrossRef PubMed
  27.Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.CrossRef PubMed
  28.Lu JJ, Crimin K, Goodwin JT, Crivori P, Orrenius C, Xing L, et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem. 2004;47(24):6104–7.CrossRef PubMed
  29.Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002;54(3):355–66.CrossRef PubMed
  30.Mechoulam H, Pierce EA. Expression and activation of STAT3 in ischemia-induced retinopathy. Invest Ophthalmol Vis Sci. 2005;46(12):4409–16.CrossRef PubMed
  31.Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Cα-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol. 2010;160(5):1195–211.PubMedCentral CrossRef PubMed
  32.Lee S-H, Zahoor M, Hwang J-K, Choi K-Y. Valproic acid induces cutaneous wound healing in vivo and enhances keratinocyte motility. PLoS ONE. 2012;7(11):e48791.PubMedCentral CrossRef PubMed
  33.Gu J-W, Makey KL, Tucker KB, Chinchar E, Mao X, Pei I, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc Cell. 2013;5(1):9.PubMedCentral CrossRef PubMed
  34.Zhou J, Farah BL, Sinha RA, Wu Y, Singh BK, Bay B-H, et al. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance. PLoS ONE. 2014;9(1):e87161.PubMedCentral CrossRef PubMed
  35.Manohar M, Fatima I, Saxena R, Chandra V, Sankhwar PL, Dwivedi A. (−)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem. 2013;24(6):940–7.CrossRef PubMed
  36.Punathil T, Tollefsbol TO, Katiyar SK. EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Commun. 2008;375(1):162–7.PubMedCentral CrossRef PubMed
  37.Chang C-W, Hsieh Y-H, Yang W-E, Yang S-F, Chen Y, Hu D-N. Epigallocatechingallate inhibits migration of human uveal melanoma cells via downregulation of matrix metalloproteinase-2 activity and ERK1/2 pathway. BioMed Res Int. 2014. doi:10.​1155/​2014/​141582 .
  38.Chen Y-J, Cheng Y-J, Hung AC, Wu Y-C, Hou M-F, Tyan Y-C, et al. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol Oncol. 2013;131(3):734–43.CrossRef PubMed
  39.Shimizu M, Adachi S, Masuda M, Kozawa O, Moriwaki H. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res. 2011;55(6):832–43.CrossRef PubMed
  40.Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin EGCG. Int J Mol Sci. 2008;9(6):1034–49.PubMedCentral CrossRef PubMed
  41.Yuan J, Liu H, Kang X, Zou G. Molecular docking of epidermal growth factor receptor tyramine kinase domain and its inhibitor genistein. Chin J Biotechnol. 2008;24(10):1813–7.
  42.Chang C, Lee S, Yeh S, Chang T. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2013;33(25):3225–34.CrossRef PubMed
  43.Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinogen. 2011;10(1):20.CrossRef
  44.Zhu M-L, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15(4):841–9.PubMedCentral CrossRef PubMed
  45.Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007;7(6):591–604.CrossRef PubMed
  46.Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10(6):542.PubMedCentral CrossRef PubMed
  47.Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5(3):280–5.CrossRef PubMed
  48.Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res. 2001;7(12):4429s–35s.PubMed
  49.Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003;17(3):309–17.CrossRef PubMed
  50.Liu C, Zhang Z, Tang H, Jiang Z, You L, Liao Y. Crosstalk between IGF-1R and other tumor promoting pathways. Curr Pharm Des. 2014;20(17):2912–21.CrossRef PubMed
  51.Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011;25(4):1198–207.PubMedCentral CrossRef PubMed
  52.Farabegoli F, Barbi C, Lambertini E, Piva R. (−)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev. 2007;31(6):499–504.CrossRef PubMed
  
• 作者单位：Pushpendra Singh (1)
  Felix Bast (1)
  
  1. Centre for Biosciences, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151001, Punjab, India
  
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

Receptors for growth factors encompass within the superfamily of receptor tyrosine kinases and are known to regulate numerous biological processes including cellular growth, proliferation, metabolism, survival, cell differentiation and apoptosis. These receptors have recently caught the attention of the researchers as an attractive target to combat cancer owing to the evidence suggesting their over-expression in cancer cells. Therefore, we studied receptor-based molecular docking of IR (PDB; 3ETA), IGF1R (PDB; 1K3A), EGFR (PDB; 1M17), VEGFIR (PDB; 3HNG), and VEGFIIR (PDB; 2OH4) against natural compounds. Further, in vitro investigation of the biological effect of lead molecules in an array of cancer cell lines was done. All selected natural compounds were docked with the X-ray crystal structure of selected protein by employing GLIDE (Grid-based Ligand Docking with Energetics) Maestro 9.6. InterBioScreen natural compounds docked with each selected protein molecules by using GLIDE high throughput virtual screening. On the basis of Gscore, we select 20 compounds along with 68 anticancer compounds for GLIDE extra precision molecular docking. It was discovered in this study that compound epigallocatechin gallate (EGCG) yielded magnificent Gscore with IGF1R (PDB; 1K3A) and VEGFIIR (PDB; 2OH4), and protein–ligand interactions are chart out. Effect of EGCG on biological activity such as mRNA expression of selected protein, cell proliferation, oxidative stress, and cell migration was reported after the 48 h treatments in cancer cell lines. The RT-PCR densitometric bands analysis showed that compound EGCG reduced the mRNA expression of IGF1R, VEGFIIR, and mTOR at 80 μM concentration. Moreover, EGCG significantly reduced cell proliferation and ROS generation after 48 h treatments. Our result also indicated a reduction in the potential for cell migration that might show in vivo anti-metastasis activity of EGCG.